Don't care too much on Bell's analysts records or opinions. If you are following their recommendations, rather than your own analysis, heaven help you. Look at Grady Wulff of Bell Direct on ******, couldn't even pronounce "autologous". Practically every bio-tech analyst around the world will be offside on a 3 year return, the micro-cap bio-tech sector has been crushed globally.
But the more analysts who cover, the more exposure it gets and the more professionals do forward analysis of Striate revenues and recognise the company not going to need any more raises and should get its Remplir business and eventually ATI business going in the US and us finally down those commercialistion pathways in the US, as they've already done in both in Australia (ATI only SAS, but TGA ARTG inclusion should shortly follow). The business speaks for itself. Not that particular analysts failures, that have nothing to do with OCC.
And per this thread, media coverage, that helps too and OCC is getting more widespread exposure outside of the usual fringe finance media and WA press:
https://www.heraldsun.com.au/business/*/asx-health-stocks-forget-surgery-orthocell-says-tennis-elbow-can-be-fixed-with-its-tendon-cell-therapy/news-story/b2aa1c1ce258f71a7e2685c20a8c8bedhttps://www.copyright link/companies/healthcare-and-fitness/the-key-to-this-biotech-s-tilt-at-us-fortune-is-pure-pigs-20231030-p5eg4k(AFR if HC blocks out competitor)
